Special Reports The 10 most-anticipated drug launches of 2020

Special Reports The 10 most-anticipated drug launches of 2020

Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Earlier this week, Active Biotech, based in Lund, Sweden, announced that it was abandoning its neurology focus, including MS. The overall focus is on the company’s wholly-owned lead assets, laquinimod and tasquinimod. Laquinimod is an oral small molecule developed primarily for … Συνεχίστε να διαβάζετε Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis.

Roche’s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals

Roche's Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals

Clinical Catch-Up for the First Week of July

Clinical Catch-Up for the First Week of July

The top 10 drug launches of 2019

The top 10 drug launches of 2019

10 Biggest Drug Trials That Saw Challenges in 2018

10 Biggest Drug Trials That Saw Challenges in 2018